Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate

European Journal of Endocrinology

Volumn 165, Issue 4, 2011, Pages 647-655

  Bala, Yohann ^a,b   Farlay, Delphine ^a,b   Chapurlat, Roland D ^a,b   Boivin, Georges ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE BIOPSY; BONE CHARACTERISTICS AND FUNCTIONS; BONE CRYSTALLINITY; BONE MATRIX; BONE METABOLISM; BONE MICROHARDNESS; BONE MINERALIZATION; BONE QUALITY; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FOURIER TRANSFORM INFRARED MICROSPECTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MICRORADIOGRAPHY; OUTPATIENT DEPARTMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SPECTROSCOPY; TRABECULAR BONE; TREATMENT DURATION; VICKERS INDENTATION TEST;

EID: 80053551452     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0333     Document Type: Article

References (46)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF & Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 348 1535-1541. (doi:10.1016/S0140-6736(96)07088-2)
2. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ &Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New England Journal of Medicine 2001 344 333-340. (doi:10.1056/NEJM200102013440503)
3. Delmas PD & Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004 34 599-604. (doi:10.1016/j.bone.2003.12.022)
4. Follet H, Boivin G, Rumelhart C & Meunier PJ. The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone 2004 34 783-789. (doi:10.1016/j.bone.2003.12.012)
5. Seeman E & Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. New England Journal of Medicine 2006 354 2250-2261. (doi:10.1056/NEJMra053077)
6. Viguet-Carrin S, Garnero P & Delmas PD. The role of collagen in bone strength. Osteoporosis International 2006 17 319-336. (doi:10.1007/s00198-005- 2035-9)
7. Boivin GY, Chavassieux PM, Santora AC, Yates J & Meunier PJ. Alendronate increases bone strength by increasing themean degree of mineralization of bone tissue in osteoporotic women. Bone 2000 27 687-694. (doi:10.1016/S8756-3282(00)00376-8)
8. Boskey AL, Spevak L & Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporosis International 2009 20 793-800. (doi:10.1007/s00198-008-0725-9)
9. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P &Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001 29 185-191. (doi:10.1016/S8756-3282(01)00485-9)
10. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD & Turner RT. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006 39 345-352. (doi:10.1016/j.bone.2006.01.161)
11. Allen MR, Iwata K, Phipps R & Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006 39 872-879. (doi:10.1016/j.bone.2006.04.028)
12. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC &Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001 28 524-531. (doi:10.1016/S8756-3282(01)00414-8)
13. Allen MR, Gineyts E, Leeming DJ, Burr DB & Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis International 2008 19 329-337. (doi:10.1007/s00198-007- 0533-7)
14. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M & Dobnig H. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007 41 378-385. (doi:10.1016/j.bone.2007.04.198)
15. Giusti A, Hamdy NA & Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010 47 169-180. (doi:10.1016/j.bone.2010.05.019)
16. Visekruna M, Wilson D & McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. Journal of Clinical Endocrinology and Metabolism 2008 93 2948-2952. (doi:10.1210/jc.2007-2803)
17. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA &Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. Journal of Clinical Endocrinology and Metabolism 2005 90 1294-1301. (doi:10.1210/jc.2004-0952)
18. Richer E, Lewis MA, Odvina CV, Vazquez MA, Smith BJ, Peterson RD, Poindexter JR, Antich PP & Pak CY. Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporosis International 2005 16 1384-1392. (doi:10.1007/s00198-005-1848-x)
19. Woo SB, Hellstein JW & Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine 2006 144 753-761. (Pubitemid 46780635)
20. Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P & Klaushofer K. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). Journal of Bone and Mineral Research 2010 25 48-55. (doi:10.1359/jbmr. 090702)
21. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N & Delmas PD. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. Journal of Bone and Mineral Research 2007 22 1502-1509. (doi:10.1359/jbmr.070609)
22. Boivin G, Lips P, Ott SM, Harper KD, Sarkar S, Pinette KV &Meunier PJ. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2003 88 4199-4205. (doi:10.1210/jc.2002-022020)
23. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM & Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research 1987 2 595-610. (doi:10.1002/jbmr. 5650020617)
24. Boivin G, Bala Y, Doublier A, Farlay D, Ste-Marie LG, Meunier PJ &Delmas PD. The role of mineralization and organic matrix in the microhardness of bone tissue fromcontrols and osteoporotic patients. Bone 2008 43 532-538. (doi:10.1016/j.bone.2008.05.024)
25. Farlay D, Panczer G, Rey C, Delmas PD & Boivin G. Mineral maturity and crystallinity index are distinct characteristics of bone mineral. Journal of Bone and Mineral Metabolism 2010 28 433-445. (doi:10.1007/s00774-009-0146-7)
26. Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ & Turner RT. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005 37 1-9. (doi:10.1016/j.bone. 2005.03.017)
27. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC & Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Journal of the American Medical Association 2006 296 2927-2938. (doi:10.1001/jama.296.24.2927)
28. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC &Liberman UA. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine 2004 350 1189-1199. (doi:10.1056/NEJMoa030897)
29. Garnero P, Shih WJ, Gineyts E, Karpf DB & Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. Journal of Clinical Endocrinology and Metabolism 1994 79 1693-1700. (doi:10.1210/jc.79.6.1693)
30. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U & Santora AC II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. American Journal of Medicine 1996 101 488-501. (doi:10.1016/S0002-9343(96)00282-3)
31. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R &Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcified Tissue International 2007 81 73-80. (doi:10.1007/s00223-007-9039-8)
32. Boivin G & Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcified Tissue International 2002 70 503-511. (doi:10.1007/s00223-001-2048-0)
33. Boivin G, Bala Y, Chapurlat R & Delmas P. Long-term treatment with oral bisphosphonates in postmenopausal women: effects on the degree of mineralization and microhardness of bone. Journal of Bone and Mineral Research 2008 23 (Suppl 1) S10.
34. Brennan TC, Rizzoli R & Ammann P. Selective modification of bone quality by PTH, pamidronate, or raloxifene. Journal of Bone and Mineral Research 2009 24 800-808. (doi:10.1359/jbmr.081227)
35. Wang X, Shanbhag AS, Rubash HE & Agrawal CM. Short-term effects of bisphosphonates on the biomechanical properties of canine bone. Journal of Biomedical Materials Research 1999 44 456-460. (doi:10.1002/(SICI)1097- 4636(19990315)44:4〈456::AID-JBM12〉3.0.CO;2-9)
36. Wang X, Allen MR, Burr DB, Lavernia EJ, Jeremic B & Fyhrie DP. Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone. Bone 2008 43 775-780. (doi:10.1016/j.bone.2008.05.023)
37. Bala Y, Farlay D, Delmas PD, Meunier PJ & Boivin G. Time sequence of secondary mineralization and microhardness in cortical and cancellous bone from ewes. Bone 2010 46 1204-1212. (doi:10.1016/j.bone.2009.11.032)
38. Aydin HM, Hu B, Suso JS, El Haj A & Yang Y. Study of tissue engineered bone nodules by Fourier transform infrared spectroscopy. Analyst 2011 136 775-780. (doi:10.1039/c0an00530d)
39. Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K & Paschalis EP. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. Journal of Bone and Mineral Research 2011 26 12-18. (doi:10.1002/jbmr.180)
40. Russell RG, Watts NB, Ebetino FH & Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 2008 19 733-759. (doi:10.1007/s00198-007-0540-8)
41. Ebetino FH, Barnett BL & Russell RG. A computational model delineates differences in hydroxyapatite binding affinities of bisphosphonates in clinical use. Journal of Bone and Mineral Research 2005 20 (Suppl 1) S259.
42. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG & Ebetino FH. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006 38 617-627. (doi:10.1016/j.bone.2005.05.003)
43. Wu W, Gerard DE & Nancollas GH. Nucleation at surfaces: the importance of interfacial energy. Journal of the American Society of Nephrology 1999 10 (Suppl 14) S355-S358. (Pubitemid 29498580)
44. Yerramshetty JS & Akkus O. The associations between mineral crystallinity and the mechanical properties of human cortical bone. Bone 2008 42 476-482. (doi:10.1016/j.bone.2007.12.001)
45. Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R & Klaushofer K. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. Journal of Bone and Mineral Research 2006 21 1581-1590. (doi:10.1359/jbmr. 060701)
46. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ & Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. Journal of Clinical Investigation 1997 100 1475-1480. (doi:10.1172/JCI119668)